Novartis. This treatment is more complicated but they're throwing everything at it. DMOAD.
For Ampion, they missed the original endpoints so the trial failed. So they changed the endpoints without approval from the FDA. Even if they run another P3 trial the FDA will still consider this recent trial to be a failure, so they'll have to run even more trials.
Ampio -v- Zilosul, page-32
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.005(2.56%) |
Mkt cap ! $70.04M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 21.0¢ | 20.0¢ | $154.0K | 756.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 101195 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 22541 | 4 |
View Market Depth
| Last trade - 13.44pm 10/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |